Samsung Biologics announced on the 10th that it has signed a contract for contract manufacturing of pharmaceuticals worth approximately 1.024 trillion won ($75.39 million) with a European pharmaceutical company. The name of the contracting party was not disclosed due to business confidentiality reasons.
Under this contract, Samsung Biologics will produce the relevant pharmaceuticals until the end of 2031. With this agreement, Samsung Biologics has already surpassed half of last year's total order amount of 5.4035 trillion won, securing a total of five new contracts this year based on the disclosure.
The company stated that it plans to strengthen its order activities further by participating in the world's largest pharmaceutical and biotech fair, the "2025 BIO International Convention" in Boston, USA, on the 16th (local time).